Risk factors for venous thromboembolism.
暂无分享,去创建一个
[1] A. Kierkegaard. Incidence of acute deep vein thrombosis in two districts. A phlebographic study. , 1980, Acta chirurgica Scandinavica.
[2] S Hulley,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.
[3] M. Stampfer,et al. Epidemiology of Oral Contraceptives and Cardiovascular Disease , 1998, Annals of Internal Medicine.
[4] R. M. Vazquez,et al. Thromboembolic complications associated with L‐asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma , 1985, Cancer.
[5] G. Bannister,et al. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. , 1995, The Journal of bone and joint surgery. British volume.
[6] B. Dahlbäck,et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. , 1995, Blood.
[7] J. T. ten Cate,et al. ACQUIRED RISK FACTORS AND DEEP VEIN THROMBOSIS IN SYMPTOMATIC OUT PATIENTS , 1994, Thrombosis and Haemostasis.
[8] D. Mant,et al. Oral contraceptives and venous thromboembolism: findings in a large prospective study. , 1986, British medical journal.
[9] H. Büller,et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. , 1990, The New England journal of medicine.
[10] F. Grodstein,et al. Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study , 2001, Annals of Internal Medicine.
[11] F. Lundin,et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. , 1991, American journal of epidemiology.
[12] E. Vittinghoff,et al. Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.
[13] P. Ridker,et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.
[14] H. Jick,et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis , 2000, BMJ : British Medical Journal.
[15] M. Samama,et al. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. , 2000, Archives of internal medicine.
[16] P. Meraj,et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. , 1999, Journal of the American College of Cardiology.
[17] N Rifai,et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.
[18] J. Vandenbroucke,et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. , 1999, Archives of internal medicine.
[19] R J Hettiarachchi,et al. Undiagnosed malignancy in patients with deep vein thrombosis , 1998, Cancer.
[20] A. Kierkegaard. Incidence and Diagnosis of Deep Vein Thrombosis Associated with Pregnancy , 1983, Acta obstetricia et gynecologica Scandinavica.
[21] W. Coon,et al. Some epidemiologic considerations of thromboembolism. , 1959, Surgery, gynecology & obstetrics.
[22] C. Furberg,et al. Venous thromboembolic events associated with hormone replacement therapy. , 1997, JAMA.
[23] C. Warlow,et al. Deep venous thrombosis of the legs after strokes. Part I--incidence and predisposing factors. , 1976, British medical journal.
[24] F. Lederle. Heparin Prophylaxis for Medical Patients? , 1998, Annals of Internal Medicine.
[25] L. García-Rodríguez,et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. , 1998, American journal of epidemiology.
[26] Pieter H. Reitsma,et al. Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.
[27] D. Hosmer,et al. Physician practices in the prevention of venous thromboembolism. , 1991, Annals of internal medicine.
[28] O. Böstman,et al. Deep venous thrombosis and pulmonary embolism in patients with acute spinal cord injury: a comparison with nonparalyzed patients immobilized due to spinal fractures. , 1985, The Journal of trauma.
[29] P. Reitsma,et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. , 1994 .
[30] J. Hirsh,et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. , 1988, The New England journal of medicine.
[31] N. Gibbs,et al. Venous thrombosis of the lower limbs with particular reference to bed‐rest , 1957, The British journal of surgery.
[32] L. Melton,et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. , 2001, Mayo Clinic proceedings.
[33] P. Reitsma,et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation , 1994, The Lancet.
[34] Diederick E Grobbee,et al. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis , 2001, BMJ : British Medical Journal.
[35] H. Saito,et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five‐drug chemotherapy regimen , 1984, Cancer.
[36] T. Kjellstrom,et al. Deep venous thrombosis and occult malignancy: an epidemiological study , 1994, BMJ.
[37] J. Vandenbroucke,et al. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. , 1999, Blood.
[38] D. Hosmer,et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. , 1991, Archives of internal medicine.
[39] D. Bergqvist,et al. Cost of Long-Term Complications of Deep Venous Thrombosis of the Lower Extremities: An Analysis of a Defined Patient Population in Sweden , 1997, Annals of Internal Medicine.
[40] José A Fernández,et al. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. , 2001, Blood.
[41] I. Pinder,et al. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation. , 1993, The Journal of bone and joint surgery. British volume.
[42] A. Laupacis,et al. Use of statins and the subsequent development of deep vein thrombosis. , 2001, Archives of internal medicine.
[43] J. Carson,et al. Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.
[44] R. Bick. Coagulation Abnormalities in Malignancy: A Review , 1992, Seminars in thrombosis and hemostasis.
[45] J. Manson,et al. A prospective study of risk factors for pulmonary embolism in women. , 1997, JAMA.
[46] B. Dahlbäck,et al. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[47] E. Bromfield,et al. Relative Risk of Deep Venous Thrombosis or Pulmonary Embolism Post-Stroke Based on Ambulatory Status , 1988 .
[48] L. Libow,et al. Autopsy study of the elderly institutionalized patient. Review of 234 autopsies. , 1988, Archives of internal medicine.
[49] M. Prins,et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. , 1992, The New England journal of medicine.
[50] Jean-Yves Lefrant,et al. Complications of Femoral and Subclavian Venous Catheterization in Critically Ill Patients: A Randomized Controlled Trial , 2001 .
[51] J. Olsen,et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. , 1998, The New England journal of medicine.
[52] B. Lindblad,et al. A prospective study of the incidence of deep‐vein thrombosis within a defined urban population , 1992, Journal of internal medicine.
[53] R. Tait,et al. Risk Factors for Pregnancy Associated Venous Thromboembolism , 1997, Thrombosis and Haemostasis.
[54] W M O'Fallon,et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.
[55] Deborah Grady,et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.
[56] A prospective investigation of pulmonary embolism in women and men. , 1992, JAMA.
[57] F R Rosendaal,et al. Risk Factors for Venous Thrombotic Disease , 1999, Thrombosis and Haemostasis.
[58] G. Raskob,et al. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. , 1998, Archives of internal medicine.
[59] P. Romano,et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. , 2000, The New England journal of medicine.
[60] G. Eklund,et al. ORAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE: EFFECTS OF LOWERING ŒSTROGEN CONTENT , 1980, The Lancet.
[61] B. Barlogie,et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.
[62] W. Kannel,et al. Risk factors for pulmonary embolism: The Framingham study , 1983 .
[63] F. Rosendaal,et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.
[64] J. Vandenbroucke,et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen , 1995, The Lancet.
[65] W M O'Fallon,et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.
[66] J. Szalai,et al. A prospective study of venous thromboembolism after major trauma. , 1994, The New England journal of medicine.
[67] R. Madhok,et al. Trends in the utilization of primary total hip arthroplasty, 1969 through 1990: a population-based study in Olmsted County, Minnesota. , 1993, Mayo Clinic proceedings.
[68] H. Ory,et al. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. , 1997, Contraception.
[69] K. Newton,et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens , 1996, The Lancet.
[70] H. Liebman,et al. Depression of functional and antigenic plasma antithrombin III (AT‐III) due to therapy with L‐asparaginase , 1982, Cancer.
[71] M. Prins,et al. A Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism , 2001, Annals of Internal Medicine.
[72] P. Reitsma,et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) , 1995, Blood.
[73] A. Zwinderman,et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] L. Melton,et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.
[75] S. Schulman,et al. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. , 2000, The New England journal of medicine.
[76] T. Lindahl,et al. APC-resistance Is a Risk Factor for Postoperative Thromboembolism in Elective Replacement of the Hip or Knee – A Prospective Study , 1999, Thrombosis and Haemostasis.
[77] P. Monagle,et al. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. , 1998, The Journal of pediatrics.
[78] J. Keller,et al. Venous Thromboembolism and Other Venous Disease in the Tecumseh Community Health Study , 1973, Circulation.
[79] P. Ridker,et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.
[80] B Urquhart,et al. Effects of epidural anesthesia on the incidence of deep-vein thrombosis after total knee arthroplasty. , 1991, The Journal of bone and joint surgery. American volume.
[81] Paolo Prandoni,et al. The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.
[82] World Health Organization Collaborative Study of Cardiov Contarception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study , 1995, The Lancet.
[83] J. Martin,et al. Autopsy Proven Pulmonary Embolism in Hospital Patients: Are We Detecting Enough Deep Vein Thrombosis? , 1989, Journal of the Royal Society of Medicine.
[84] W. Coon. Risk factors in pulmonary embolism. , 1976, Surgery, gynecology & obstetrics.
[85] B. Yawn,et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. , 2001, American journal of obstetrics and gynecology.
[86] W. Spitzer,et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study , 1996, BMJ.
[87] L. Melton,et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.
[88] H. Jick,et al. Tamoxifen and risk of idiopathic venous thromboembolism. , 1998, British journal of clinical pharmacology.